Vergleich

Transforming Growth Factor Beta (TGF-beta)

Hersteller Anogen
Kategorie
Typ Antibody Monoclonal
Specific against Human
Clon TB21
Isotype IgG1 kappa
Format Aff. Pur
Applikationen WB, IHC, NT
Protein Familie Cytokine, Growth Factors
Menge 0.5mg
Host Mouse
ArtNr ANOG-MO-C40009A
eClass 6.1 32160702
eClass 9.0 42030590
Lieferbar
Description
Mouse monoclonal antibody to human Transforming Growth Factor beta (TGF-beta)
Target Protein
Human TGF-beta
Immunogen
TGF-beta from human platelets
Specificity
Western blotting demonstrated that this antibody reacts with the dimeric (25 kDa) and monomeric (12.5 kDa.) forms of TGF-beta under both non-reducing and reducing conditions respectively. This antibody recognizes both human platelet-derived and recombinant TGF-beta in ELISA.
Purification
Protein G affinity purified
Species Reactivity
Human, other species not tested
Myeloma
Sp2/0-Ag14
Background
Transforming growth factor beta (TGF-beta) has three isoforms (TGF-beta1, TGF-beta2, and TGF-beta3) with similar functions. The cytokine is a homodimer linked by disulfide bind. Inside cells, the cytokine forms a small latent complex with latent associated peptide (LAP). This small complex binds to latent TGF-beta binding protein (LTBP) to be secreted to extra-cellular matrix. Disassociation of the latent proteins from TGF-beta results in the release of the cytokine to its receptor. The process is called activation, which can be influenced by various factors, including proteases, metalloproteases, extreme pH, mild acidic condition, reactive oxygen species and integrins. TGF-beta is an anti-proliferation factor in normal cells. It increases the synthesis of p15 and p21, which can block the cyclin: CDK complex, and causes cells to stop at G1 phase. The cytokine can induce apoptosis through both SMAD and DAXX pathways. In cancer cells, TGF-beta signaling is altered and TGF-beta no longer stops cell proliferation.
Formulation
Lyophilized from a solution in 0.01M PBS, pH 7.0
Reconstitution
Double distilled water is recommended to adjust the final concentration to 1.00mg/mL.
Application info
Neutralizing: This antibody neutralizes TGF-beta activity in vitro and in vivo. In an inhibition assay of CCL/64 cell growth and in a NRK-49F colony forming assay, the antibody neutralized TGF-beta bioactivities. The effect of micro-injection of this antibody into one blastomere of two cell stage Xenopus embryos indicated that it was also able to neutralize the bioactivity of TGF-beta in vivo.
IHC: This antibody has been used to demonstrate TGF-beta in ovine ovarian tissue and human breast carcinoma at a dilution of 1:1000. As a consequence of the intense staining of the erythrocytes, it is possible to locate a single cell within the ovarian stroma, making it useful in locating very fine capillary networks within tissue.
Western Blot: This antibody when used at concentration of 5-20ng/mL will allow visualization of 100ng/lane of TGF-beta.
Research Area
Growth Factors and Their Receptors, Angiogenesis
Storage
Store at -20C
Reference
Crawford, S. E. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159-1170 (1998)
Biological characterization of a monoclonal antibody TB21 against human transforming growth factor-beta 1. Acta Biologiae Experimentalis Sinica Vol. 26, No. 2 June (1993).

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 0.5mg
Lieferbar: In stock
lieferbar

Lieferung vsl. bis 13.05.2024 

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen